Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial

Cardiovascular Diabetology

  ^{1    1    1    1    2    3} 

[1] 0000 0001 0629 5880, grid.267309.9, Cardiology Division, University Texas Health Science Center at San Antonio, 7403 Wurzbach Road, 78229, San Antonio, TX, USA;0000 0001 2184 9220, grid.266683.f, Cardiology Division, University of Massachusetts Medical School-Baystate, Springfield, MA, USA;0000 0004 4686 9756, grid.416653.3, Cardiology Division, Brooke Army Medical Center, San Antonio, TX, USA;

关键词: Omega-3 polyunsaturated fatty acids;    Hypertriglyceridemia;    Hyperlipidemia;    Diabetes mellitus;   

DOI  :  10.1186/s12933-019-0887-0

来源: publisher

【 摘 要 】

Heart disease continues to affect health outcomes globally, accounting for a quarter of all deaths in the United States. Despite the improvement in the development and implementation of guideline-directed medical therapy, the risk of adverse cardiac events remains substantially high. Historically, it has been debated whether omega-3 polyunsaturated fatty acids provide clinical benefit in cardiac disease. The recently published REDUCE-IT trial demonstrated a statistically significant absolute risk reduction of 4.8% in its primary endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina) with the use of icosapent ethyl, which is a highly purified eicosapentaenoic acid (EPA) ethyl ester. However, the mechanism of action of omega-3 fatty acids is not commonly discussed. Moreover, the use of EPA was not without risk, as the incidence of atrial fibrillation was increased along with a trend towards increased bleeding risk. Thus, our aim is to help explain the function of purified EPA ethyl ester, especially at the molecular level, which will ultimately lead to a better understanding of their clinically observable effects.

【 授权许可】

CC BY